The control of abstinence in the treatment of alcohol dependence: the use of acamprosate in relapse prevention


Submitted: November 21, 2013
Accepted: November 21, 2013
Published: January 10, 2014
Abstract Views: 1299
PDF: 903
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Fabio Venturella Department of Sciences for Health Promotion G. D’Alessandro, University of Palermo, Italy.
  • Anna Asaro Department of Sciences for Health Promotion G. D’Alessandro, University of Palermo, Italy.
  • Guido Faillace Alcamo Drug Addiction Service, Alcamo, Italy.
  • Gianpaolo Spinnato Psichiatry Institute, Local Health Service 2, Palermo, Italy.
  • Danila Di Majo Department of Law, Society and Sports Studies, University of Palermo, Italy.
  • Maurizio La Guardia Department of Law, Society and Sports Studies, University of Palermo, Italy.
  • Marco Giammanco Department of Law, Society and Sports Studies, University of Palermo, Italy.
  • Stefania Aiello Department of Molecular and Biomolecular Sciences and Technologies, University of Palermo, Italy.
Treatment with acamprosate is a valid tool to complement psychotherapy as it does not cause addiction, abuse or withdrawal of its suspension and does not interfere with other medications that patients often alcoholics must take. To evaluate the effectiveness, our study evaluated the effects of Acamprosate compared to γ-hydroxybutyrate in clinical-physiological and social health in a way indicator of a possible therapeutic success in terms of abstinence from alcohol and social reintegration. A total of 36 patients were observed, of which 5, 4 men and 1 woman at the Drug Addiction Service (Servizio Tossicodipendenze, Ser.T) Alcamo, and 31, 21 men and 10 women at the Ser.T of Palermo. As regards the craving, during the period of treatment with acamprosate, there has been a change, in the sense of reduction, of craving for alcohol: if before therapy was in 68% of cases, medium-high, it becomes after 3-4 months of therapy in low-nil in 89% of patients observed. It has been recorded that, after 3-4 months after receiving acamprosate, the clinical picture of the patient is greatly improved by referring to biological markers. In particular, the strong point seems to be the ability for the user to experience a new sense of normalcy and to remove the desire for significant periods of alcohol.

Venturella, F., Asaro, A., Faillace, G., Spinnato, G., Di Majo, D., La Guardia, M., Giammanco, M., & Aiello, S. (2014). The control of abstinence in the treatment of alcohol dependence: the use of acamprosate in relapse prevention. Journal of Biological Research - Bollettino Della Società Italiana Di Biologia Sperimentale, 87(1). https://doi.org/10.4081/jbr.2014.2142

Downloads

Download data is not yet available.

Citations